GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » PB Ratio

NRXP (NRX Pharmaceuticals) PB Ratio : (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NRX Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-11), NRX Pharmaceuticals's share price is $1.19. NRX Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 was $-1.66. Hence, NRX Pharmaceuticals's PB Ratio of today is .

The historical rank and industry rank for NRX Pharmaceuticals's PB Ratio or its related term are showing as below:

During the past 4 years, NRX Pharmaceuticals's highest PB Ratio was 59.04. The lowest was 0.00. And the median was 0.00.

NRXP's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.54
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was 46.70% per year.

During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of NRX Pharmaceuticals was 46.70% per year. The lowest was 46.70% per year. And the median was 46.70% per year.

Back to Basics: PB Ratio


NRX Pharmaceuticals PB Ratio Historical Data

The historical data trend for NRX Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals PB Ratio Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PB Ratio
- 13.51 9.96 -

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NRX Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, NRX Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NRX Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's PB Ratio falls into.



NRX Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

NRX Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=1.19/-1.655
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


NRX Pharmaceuticals  (NAS:NRXP) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


NRX Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NRX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Executives
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz director C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Jonathan C Javitt director, 10 percent owner, officer: Chief Scientist 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard director, officer: Chief Executive Officer 1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt 10 percent owner 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg officer: Chief Financial Officer C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof officer: Chief Comm. & Patient Officer 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault officer: General Counsel & Secretary 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster director C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
Sharon Glied director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Ackerman director, 10 percent owner, officer: President & CEO 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Big Rock Partners Sponsor, Llc 10 percent owner 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483

NRX Pharmaceuticals Headlines

From GuruFocus